Explore

Rapid Read Rapid Read
Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

Experimental Drug Shows Promise in Extending Survival for Pancreatic Cancer Patients

An experimental drug, daraxonrasib, has shown promising results in a Phase 3 clinical trial for patients with metastatic pancreatic cancer. The trial, which enrolled 500 patients, revealed that those treated with daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those receiving chemotherapy. The drug, designed to block RAS proteins, reduced the risk of death by 60%. These findings were presented at the American Society of Clinical Oncology annual meeting and published in the New England Journal of Medicine.
Rapid Read Rapid Read
Citius Oncology Presents Phase 1 Data on LYMPHIR in Combination with Pembrolizumab for Gynecologic Malignancies

Citius Oncology Presents Phase 1 Data on LYMPHIR in Combination with Pembrolizumab for Gynecologic Malignancies

Citius Oncology has presented Phase 1 clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting, evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab for recurrent or refractory gynecologic malignancies. The study demonstrated durable responses and manageable tolerability in heavily pre-treated patients, with a 20.5-month median progression-free survival observed among 48% of efficacy-evaluable patients. The combination therapy showed a 33% objective response rate in patients with relapsed or refractory endometrial cancer. LYMPHIR's ability to deplete immunosuppressive regulatory T-cells may enhance the effect of checkpoint inhibitors, offering a potential therapeutic option for patients with limited treatment options.
Rapid Read Rapid Read
Clinical Trials Show Promising Results for Cancer Treatment Injection

Clinical Trials Show Promising Results for Cancer Treatment Injection

Recent clinical trials have demonstrated promising results for a cancer treatment injection known as amivantamab, developed by Johnson & Johnson. The drug was tested in an 11-nation trial involving patients whose cancer had either spread or returned after other treatments failed. The trial included 102 patients with head and neck cancer, where tumors shrank or disappeared in 43 patients. Notably, 28 patients experienced tumor shrinkage, while 15 saw their tumors completely disappear. The injection has also shown similar results in patients with certain types of lung cancer, with tumors shrinking in more than a third of patients. The drug works by targeting a protein that aids tumor growth and blocking pathways used by cancer cells to resist treatment, while also activating the immune system to assist in treatment. The results of the trial are set to be presented at the American Society of Clinical Oncology annual meeting in Chicago.
Rapid Read Rapid Read
MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR's New Therapeutic Strategy Shows Promise in Advanced Prostate Cancer Treatment

MEDSIR, an international oncology research company, has presented the final results of its ZZ-FIRST study at the ASCO scientific congress in Chicago. The study explores a new therapeutic strategy for patients with high-volume metastatic hormone-sensitive prostate cancer. This approach combines enzalutamide, a next-generation hormonal treatment, with talazoparib, a PARP inhibitor, to intensify standard therapy. The goal is to block tumor progression before the cancer develops resistance to treatment. The study enrolled 54 patients from Spanish centers and demonstrated that the combination therapy resulted in a radiographic progression-free survival of 45.3 months, compared to 31.1 months with enzalutamide alone. This suggests a significant improvement in delaying tumor progression.
Rapid Read Rapid Read
Kelun-Biotech Presents Promising Phase III Lung Cancer Study Results at ASCO

Kelun-Biotech Presents Promising Phase III Lung Cancer Study Results at ASCO

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of their Phase III clinical study, OptiTROP-Lung05, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study evaluated the efficacy of sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab (KEYTRUDA®) as a first-line treatment for non-small cell lung cancer (NSCLC) with a PD-L1 Tumor Proportion Score of 1% or higher. The study involved 413 patients and demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) when compared to pembrolizumab alone. The combination therapy showed a median PFS that was not reached, compared to 5.7 months for pembrolizumab alone, and a 12-month PFS rate of 62.4% versus 29.0%. The study also reported a positive trend in OS, with a 12-month OS rate of 80.4% versus 68.9%. The safety profile of the combination was manageable, with no new safety signals identified.
Rapid Read Rapid Read
NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

NYU Langone Health Study Shows Cancer Vaccine Reduces Melanoma Recurrence by 49%

A study led by NYU Langone Health and its Perlmutter Cancer Center has demonstrated that a combination of a vaccine, intismeran, and the immunotherapy drug pembrolizumab (Keytruda) can significantly reduce the risk of melanoma recurrence and death. The phase 2b trial, known as KEYNOTE-942, involved 107 patients who had undergone melanoma surgery. The results, presented at the 2026 annual meeting of the American Society of Clinical Oncology, showed that the combination therapy reduced the risk of cancer recurrence or death by 49% compared to the standard treatment of pembrolizumab alone. Additionally, the combination therapy reduced the risk of distant metastasis by 59%. The study highlights the potential of mRNA vaccines like intismeran in enhancing the effectiveness of immunotherapy for cancers with high mutation rates.
Rapid Read Rapid Read
Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

Personalized mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence

A clinical trial has demonstrated the potential of a personalized mRNA vaccine in reducing the recurrence of melanoma. Conducted by researchers at NYU Langone Health, the trial involved 157 patients in Australia and the U.S. who had undergone surgery to remove their tumors. The study combined the mRNA vaccine with Keytruda, an immunotherapy drug, and showed that 68.8% of patients remained cancer-free after five years, compared to 49.1% who received Keytruda alone. The results, presented at the American Society of Clinical Oncology conference, highlight the vaccine's ability to train T cells to recognize and target specific neoantigens, enhancing the immune system's response to cancer.
Trendline Trendline
Kelonia Therapeutics Reports Positive Phase 1 Results for KLN-1010 CAR-T Therapy in Multiple Myeloma Patients

Kelonia Therapeutics Reports Positive Phase 1 Results for KLN-1010 CAR-T Therapy in Multiple Myeloma Patients

Kelonia Therapeutics Reports Positive Phase 1 Results for KLN-1010 CAR-T Therapy in Multiple Myeloma Patients
AP News AP News
Experimental pill promises new hope for deadly pancreatic cancer

Experimental pill promises new hope for deadly pancreatic cancer

New research shows a novel pill is helping people with advanced pancreatic cancer live longer
Rapid Read Rapid Read
Revolution Medicines Develops Promising New Pill for Pancreatic Cancer Treatment

Revolution Medicines Develops Promising New Pill for Pancreatic Cancer Treatment

Revolution Medicines has developed a new drug, daraxonrasib, targeting the KRAS gene mutation prevalent in pancreatic cancer patients. The drug has shown promising results in clinical trials, nearly doubling the survival rate of patients compared to standard chemotherapy. The pill is part of a class of drugs known as RAS inhibitors and has been tested on patients with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The trial results indicate that the drug could significantly improve treatment outcomes for this deadly cancer, which has a low five-year survival rate. The drug has been fast-tracked for limited approval by the FDA, although it is not yet widely available.
Trendline Trendline
Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients
Rapid Read Rapid Read
Clinical Trial Shows Daraxonrasib Doubles Survival Time for Advanced Pancreatic Cancer Patients

Clinical Trial Shows Daraxonrasib Doubles Survival Time for Advanced Pancreatic Cancer Patients

A clinical trial has revealed that a daily pill, daraxonrasib, can significantly extend the survival time for patients with advanced pancreatic cancer. The trial, involving 500 patients, demonstrated that those who took daraxonrasib lived an average of 13.2 months, compared to 6.6 to 6.7 months for those undergoing chemotherapy. This drug targets the Kras protein, which is involved in the growth of nearly all pancreatic cancers. The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, where experts hailed the drug as a 'gamechanger' in cancer treatment. The trial was led by researchers at the Dana-Farber Cancer Institute in Boston.